Table 2 Lotinib/gefitinib response and EGFR mutations of 29 lung cancer patients.
Cases | Cancer subtype | Drug responses | Tumor stage | EGFR mutation | ERBB2 amplification | |||
|---|---|---|---|---|---|---|---|---|
1 | LUAD | R | IV | T790M | L858R | |||
2 | LUAD | R | III | T790M | L858R | |||
3 | LUAD | R | IV | L858R | ||||
4 | LUAD | R | – | T790M | L858R | |||
5 | LUAD | R | IV | T790M | L858R | |||
6 | LUAD | R | III | L858R | yes | |||
7 | LUAD | R | IV | T790M | 19 exon del | Amplification | ||
8 | LUAD | R | – | 19 exon del | Amplification | |||
9 | LUAD | R | IV | T790M | 19 exon del | Amplification | ||
10 | SCLC | R | IV | 19 exon del | Amplification | |||
11 | LUAD | R | IV | T790M | 19 exon del | Amplification | ||
12 | LUAD | R | IV | T790M | 19 exon del | Amplification | ||
13 | LUAD | R | IV | T790M | 19 exon del | Amplification | ||
14 | LUSC | R | IV | T790M | 19 exon del | Amplification | ||
15 | LUAD | R | III | 19 exon del | yes | |||
16 | LUAD | R | IV | T790M | 19 exon del | |||
17 | LUAD | R | – | 19 exon del | ||||
18 | LUAD | R | – | 19 exon del | ||||
19 | NSCLC | R | IV | 19 exon del | ||||
20 | LASC | R | IV | Amplification | ||||
21 | SCLC | R | IV | Amplification | ||||
22 | LUAD | R | – | T790M | Amplification | L858R | ||
23 | LUAD | S | IV | T790M | 19 exon del | |||
24 | NSCLC | S | – | T790M | 19 exon del | |||
25 | LUAD | S | IV | T790M | 19 exon del | |||
26 | LUAD | S | IV | 19 exon del | ||||
27 | LUAD | S | – | 19 exon del | ||||
28 | LUAD | S | IV | T790M | 19 exon del | Amplification | ||
29 | LUAD | S | I | L858R | ||||
